Abstract:Background While the past decades have seen an explosion of innovation in immunotherapies, most have failed in their clinical studies. One of the barriers encountered across these trials is that despite demonstrated cytoxicity, tumor immune evasion renders these treatments ineffective. Glioblastoma (GBM) is one of these tumors where experimental immunotherapeutics have continued to fail. The median survival of GBM remains at 15 months with the primary treatment being surgical resection, radiation, and chemotherapeutic over the past decade. To breach this stalemate, we require new therapeutics that both can target tumor immune evasion and can balance efficacy with toxicity. Our lab previously developed a subcutaneous autologous tumor vaccine utilizing a phagocytosis-stimulating ligand mannan anchored to irradiated (IR) tumor cells with the adjuvants toll-like receptor (TLR) agonists and immunostimulant anti-CD40 antibody (collectively abbreviated as MBTA). This regime allowed recognition of tumors resulting in a coordinated innate and adaptive immune response in both prophylactic and therapeutic studies with colon carcinoma, breast tumor, and GBM mouse models. The aim of our study was to generate a dendritic cell (DC) vaccine utilizing this strategy. Methods To assess if MBTA anchored GBM cells could mature DCs in-vitro, we harvested bone-marrow DCs (BMDCs) from mice and co-cultured them with MBTA GBM cells for 24 hours. Analysis was performed by flow cytometry and ELISA to confirm maturation markers and DC phenotype. To assess if MBTA DCs could protect against tumor metastasis, we utilized a melanoma (B16) prophylactic model by vaccinating mice 1 week before tail vein melanoma challenge. Results We found robust up-regulation of co-stimulatory molecules CD40, CD80 and CD86 and preferential upregulation of MHCI in the MBTA group with ELISA analysis demonstrating MBTA DCs significantly upregulated Type 1 cytokines (TNFa and IL-6) and limited regulatory cytokine (IL-10) secretion across GBM cell lines. Mice vaccinated with MBTA DCs had a significant decrease in lung metastasis compared to controls with lung immunohistochemistry demonstrating robust perivascular lymphocytic infiltration. Currently, we are working on demonstrating this efficacy in a glioblastoma model. Conclusions Collectively our results demonstrate that MBTA is an effective strategy to mature and load tumor antigens onto DCs ex-vivo. It has efficacy as a DC vaccine to prevent melanoma metastasis and potential as a glioblastoma DC vaccine. Acknowledgements The authors acknowledge the NCI-CCR affiliated staff for their assistance with animal housing and the NCI CCR Flow Cytometry Core Members for their expertise in flow cytometry Ethics Approval The National Cancer Institute (NCI) Animal Use and Care Committees approved the present study under NOB-010 and NOB-016.

Activation of Cytotoxic T Lymphocytes Against CML28-bearing Tumors by Dendritic Cells Transduced with a Recombinant Adeno-Associated Virus Encoding the CML28 Gene.

Dendritic Cells Tranfected with CML-28 Cdna Induce CML28-Specific Cytotoxic T Cells.

Potent antitumor activity of the Ad5/11 chimeric oncolytic adenovirus combined with interleukin-24 for acute myeloid leukemia via induction of apoptosis.

Anti-tumor immunity against nasopharyngeal carcinoma by means of LMP2A-specific cytotoxic T lymphocytes induced by dendritic cells.

[Dendritic Cells Infected by Recombinant Adeno-Associated Virus with CEA Gene to Induce Antigen-Specific CTL Response to CD44(+)CD24(-/low) Cells from MCF-7 Breast Cancer Cell Line].

More Than Chemotaxis: A New Anti-Tumor DC Vaccine Modified by Raav2-Slc

The Biological Characteristics of Dendritic Cells Derived in Vitro from Myelogeneous Leukemia Cells and Healthy Donor Cells.

Identification of a new HLA-A*0201-restricted cytotoxic T lymphocyte epitope from CML28

Chronic Myelocytic Leukemia (CML) Patient-Derived Dendritic Cells Transfected with Autologous Total RNA Induces CML-Specific Cytotoxicity

[Construction of Genetically Modified Dendritic Cell Vaccine Expressing Bcr/abl Fusion Gene and Inducing Specific Cytotoxic T Lymphocytes to Kill K562 Cells in Vitro].

Dendritic Cell Generated from CD34+ Hematopoietic Progenitors Can Be Transfected with Adenovirus Containing Gene of HBsAg and Induce Antigen-Specific Cytotoxic T Cell Responses.

425 A Novel Dendritic Cell Vaccine Utilizing Mannan Anchored to Irradiated Tumor Cells in the Presence of Immune Adjuvants

Efficient Generation of Cytotoxic T Lymphocytes Against Cervical Cancer Cells by Adeno-Associated Virus/human Papillomavirus Type 16 E7 Antigen Gene Transduction into Dendritic Cells

Recombinant adeno-associated virus encoding secondary lymphoid tissue chemokine(rAAV-SLC) efficiently infected mouse BMDC

Clinical Safety of Induced CTL Infusion Through Recombinant Adeno-Associated Virus-Transfected Dendritic Cell Vaccination in Chinese Cancer Patients

Rationally Designed Capsid and Transgene Cassette of AAV6 Vectors for Dendritic Cell‐based Cancer Immunotherapy

CCL3 and CCL20-recruited Dendritic Cells Modified by Melanoma Antigen Gene-1 Induce Anti-Tumor Immunity Against Gastric Cancer Ex Vivo and in Vivo

In Vitro Anti-Tumor Immune Response Induced by Dendritic Cells Transfected with Recombinant Adenovirus Carrying Mutant K-Ras Genes

Induction of Tumor Immunity and Cytotoxic T Lymphocyte Responses Using Dendritic Cells Transduced by Adenoviral Vectors Encoding HBsAg: Comparison to Protein Immunization

Comparative Analysis of Cytotoxic T Lymphocyte Response Induced by Dendritic Cells Pulsed with Recombinant Adeno-Associated Virus Carrying Α-Fetoprotein Gene or Cancer Cell Lysate.

Anti-tumor effect of cytotoxicity T lymphocytes activated by dendritic cells loaded with salivary adenoid cystic carcinoma antigen